Table 1. Primary diagnoses and primary... | American Society of Hematology

Table 1.

Primary diagnoses and primary cytotoxic therapy received by 306 patients in whom t-MDS/t-AML developed

Primary diagnosis	No. patients	CT only (%)	RT only (%)	CMT (%)
No malignancy	18	12 (67)	2 (11)	4 (22)
Hematologic malignancy	171	69 (40)	5 (3)	97 (57)
Hodgkin disease	77	18 (23)	4 (5)	55 (71)
Non-Hodgkin lymphoma	70	33 (47)	1 (1)	36 (51)
Myeloma	23	17 (74)	0	6 (26)
Other^*	1	1 (100)	0	0
Solid tumor	117†	40 (35)	36 (32)	38 (33)
Breast	32‡	11 (35)	5 (16)	15 (48)
Ovary	15	12 (80)	1 (7)	2 (13)
Prostate	13§	0	11 (100)	0
Lung	9	5 (56)	2 (22)	2 (22)
Cervix	7	0	4 (57)	3 (43)
Other^*	41	12 (29)	13 (32)	16 (39)
Totals	306†	121 (40)	43 (14)	139 (46)

Primary diagnosis	No. patients	CT only (%)	RT only (%)	CMT (%)
No malignancy	18	12 (67)	2 (11)	4 (22)
Hematologic malignancy	171	69 (40)	5 (3)	97 (57)
Hodgkin disease	77	18 (23)	4 (5)	55 (71)
Non-Hodgkin lymphoma	70	33 (47)	1 (1)	36 (51)
Myeloma	23	17 (74)	0	6 (26)
Other^*	1	1 (100)	0	0
Solid tumor	117†	40 (35)	36 (32)	38 (33)
Breast	32‡	11 (35)	5 (16)	15 (48)
Ovary	15	12 (80)	1 (7)	2 (13)
Prostate	13§	0	11 (100)	0
Lung	9	5 (56)	2 (22)	2 (22)
Cervix	7	0	4 (57)	3 (43)
Other^*	41	12 (29)	13 (32)	16 (39)
Totals	306†	121 (40)	43 (14)	139 (46)

Smaller diagnostic groups were not further subdivided by primary diagnosis.

In 3 patients, the primary therapy was incompletely known.

In 1 patient, the primary therapy was incompletely known.

In 2 patients, the primary therapy was incompletely known.